|1.||Ullrich, Thomas: 3 articles (05/2006 - 05/2004)|
|2.||Rice, Kenner C: 3 articles (05/2006 - 05/2004)|
|3.||Slifstein, Mark: 2 articles (12/2011 - 11/2011)|
|4.||Xu, Xiaoyan: 2 articles (12/2011 - 11/2011)|
|5.||Abi-Dargham, Anissa: 2 articles (12/2011 - 11/2011)|
|6.||Ohara, Shinya: 1 article (03/2015)|
|7.||Tsutsui, Ken-Ichiro: 1 article (03/2015)|
|8.||Ishii, Hironori: 1 article (03/2015)|
|9.||Tobler, Philippe N: 1 article (03/2015)|
|10.||Iijima, Toshio: 1 article (03/2015)|
|1.||Schizophrenia (Dementia Praecox)
08/01/1999 - "With these data, clear go/no-go decision points could be established early within the clinical drug development process, and the selection of M100907 doses to carry forward into large-scale clinical trials in patients with schizophrenia could be narrowed."
03/01/2000 - "The 5HT(2A) receptor occupancy was determined in two patients with schizophrenia treated with M100907, 20 mg once a day. "
03/01/2000 - "To test if the suggested clinical dose of 20 mg M100907 daily induces high 5HT(2A) receptor occupancy in patients with schizophrenia. "
07/01/1998 - "These results suggest that M100907 might be an antidote for treating the PCP-induced psychotomimetic state that closely resembles schizophrenia; they could also account for the antipsychotic potential of M100907. "
01/01/1996 - "These results suggest that MDL 100,907 may have a unique interaction with dopaminergic systems and support the further development of selective 5-HT2 receptor antagonists as a novel therapeutic strategy for schizophrenia."
|2.||Autistic Disorder (Autism)
04/01/2005 - "A final study demonstrated the ability of M100907 (0.5 mg/kg) to reverse hyperthermia produced by (+)-MDMA (12 mg/kg). "
04/01/2005 - "The present studies examined the ability of the selective 5-HT(2A)R antagonist M100907 to block hyperactivity and hyperthermia produced across the (+)-MDMA dose-effect curve. "
04/01/2005 - "Additionally, we investigated the ability of M100907 (0 and 0.5 mg/kg) to reverse hyperthermia elicited by (+)-MDMA (12 mg/kg). "
01/01/2002 - "3. Pretreatment with the 5-HT(1/2) antagonist methysergide (10 mg kg(-1)), the 5-HT(2A) antagonist MDL 100,907 (0.1 mg kg(-1)) or the 5-HT(2C) antagonist SB 242084 (3 mg kg(-1)) failed to alter the hyperthermia. "
05/01/2004 - "In further hyperthermia studies, 32 mg/kg MDMA was administered first and temperature was allowed to rise for 30 min; 10 mg/kg nantenine, 1 mg/kg prazosin, or 1 mg/kg M100907 was then administered in an attempt to reverse MDMA-induced hyperthermia. "
|1.||5-HT2A Serotonin Receptor (5 HT2A Receptor)
|2.||Risperidone (Risperdal Consta)
|4.||Dizocilpine Maleate (Dizocilpine)
|6.||Serotonin 5-HT2 Receptor Antagonists
|7.||Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)
|9.||Levodopa (L Dopa)
|1.||Induced Hyperthermia (Thermotherapy)